Spectral Medical (TSE:EDT) has released an update.
Spectral Medical Inc. has announced a significant milestone in their Tigris trial, achieving a record-breaking enrollment of 116 patients as of June 2024. This surge includes the highest monthly enrollment to date, bringing the trial closer to its completion with only 34 more participants required. The company is advancing PMX, a potential septic shock treatment device, with the aim of obtaining U.S. FDA approval.
For further insights into TSE:EDT stock, check out TipRanks’ Stock Analysis page.
